Dauntless Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Octreotide Formulation For Intranasal Delivery
Dauntless Pharmaceuticals, Inc | February 16, 2017
Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, today announced the initiation of a Phase 1 clinical study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DP1038, a novel formulation of octreotide acetate for intranasal administration, compared to subcutaneous Sandostatin® (octreotide acetate) injection in healthy volunteers.